EP Patent

EP3054954A4 — Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma

Assigned to H Lee Moffitt Cancer Center and Research Institute Inc · Expires 2017-12-13 · 8y expired

What this patent protects

Patent listed against Imbruvica.

Drugs covered by this patent

Patent Metadata

Patent number
EP3054954A4
Jurisdiction
EP
Classification
—
Expires
2017-12-13
Drug substance claim
No
Drug product claim
No
Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.